Australia's TGA seals regulatory MoU (memorandum of understanding) with Switzerland:
This article was originally published in Clinica
Executive Summary
The regulation and post-market monitoring of medical devices and medicines in Australia is to be strengthened by a memorandum of understanding (MoU) with the Swiss therapeutic products regulator, Swissmedic. The MoU effectively formalises co-operative arrangements between Swissmedic and Australia's regulatory agency, the Therapeutic Goods Administration (TGA). The MoU will affect regulatory decision-making in three key areas: the global device vigilance exchange programme; Good Manufacturing Practice (GMP) inspections for medicines; and complementary medicines.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.